Oppenheimer initiated coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note issued to investors on Tuesday morning, The Fly reports. The firm issued an outperform rating and a $52.00 price objective on the stock. Oppenheimer also issued estimates for Apellis Pharmaceuticals’ Q2 2019 earnings at ($0.80) EPS, Q3 2019 earnings at ($0.84) EPS, Q4 2019 earnings at ($0.84) EPS, FY2019 earnings at ($3.34) EPS, Q1 2020 earnings at ($0.82) EPS, Q2 2020 earnings at ($0.82) EPS, Q3 2020 earnings at ($0.84) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.30) EPS, FY2021 earnings at ($3.01) EPS, FY2022 earnings at ($0.94) EPS and FY2023 earnings at $9.19 EPS.
APLS has been the subject of a number of other reports. Robert W. Baird assumed coverage on shares of Uniqure in a research note on Thursday, March 28th. They set an outperform rating and a $85.00 target price for the company. ValuEngine upgraded shares of Vistra Energy from a hold rating to a buy rating in a research note on Wednesday, July 3rd. Cantor Fitzgerald reiterated a buy rating and set a $107.00 target price on shares of Perrigo in a research note on Wednesday, May 8th. Cowen restated a hold rating on shares of Sunesis Pharmaceuticals in a research note on Sunday, June 16th. Finally, Zacks Investment Research upgraded HANNOVER RUECK/S from a sell rating to a hold rating in a research note on Friday, May 17th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Apellis Pharmaceuticals currently has a consensus rating of Buy and an average price target of $45.43.
Shares of APLS opened at $26.12 on Tuesday. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -11.16 and a beta of 0.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.23 and a current ratio of 15.23. The company’s fifty day moving average is $22.72. Apellis Pharmaceuticals has a 1-year low of $11.45 and a 1-year high of $27.41.
Several large investors have recently bought and sold shares of the company. Rhumbline Advisers raised its holdings in shares of Apellis Pharmaceuticals by 47.9% during the 4th quarter. Rhumbline Advisers now owns 47,040 shares of the company’s stock worth $620,000 after buying an additional 15,225 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Apellis Pharmaceuticals by 21.3% during the 4th quarter. Prudential Financial Inc. now owns 223,260 shares of the company’s stock worth $2,958,000 after buying an additional 39,130 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 35.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock worth $124,000 after buying an additional 2,440 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Apellis Pharmaceuticals by 30.8% during the 4th quarter. BlackRock Inc. now owns 3,730,626 shares of the company’s stock worth $49,208,000 after buying an additional 877,431 shares in the last quarter. Finally, Private Advisor Group LLC acquired a new position in shares of Apellis Pharmaceuticals during the 4th quarter worth $187,000. Hedge funds and other institutional investors own 63.45% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Featured Article: Intrinsic Value
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.